Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2011

View Archived Issues

Germline SNPs inked to outcome of docetaxel-treated metastatic castration-resistant prostate cancer

Soluble CD276 antigen in expressed prostatic secretions is a biomarker of chronic prostatitis

RITA has synergistic activity with chemotherapeutic agents in MM cells in vitro

Regeneron reports new phase III data on Arcalyst for prevention of gout flares

New modified sesamol derivative INV-403 suppresses atherosclerosis in vivo

Nile Therapeutics and Medtronic collaborate on development of cenderitide

New phase II trial evaluates Prostvac with docetaxel in prostate cancer

New inhibitors of cGMP-specific 3',5'-cyclic phosphodiesterase claimed

Pfizer completes acquisition of King Pharmaceuticals

New inhibitors patented of enoyl-[acyl-carrier-protein] reductase [NADH]

Kyorin and Almirall sign license agreement for aclidinium bromide in Japan

Daiichi Sankyo to acquire Plexxikon

Medivir's Xerese launched in the U.S. as prescription cold sore treatment

FDA grants Epeius' anticancer gene therapy Rexin-G phase III status

Mochida Pharma requests Japanese approval for Beselna in solar keratoses

Novartis seeks approval in Japan for Certican to prevent renal transplant rejection

Gemzar approved in Japan for ovarian cancer after chemotherapy

Novavax receives contract to develop flu vaccines for U.S. government

Seattle Genetics and Millennium begin phase I trial of brentuximab vedotin

Oxygen Biotherapeutics receives grant from U.S. army to study Oxycyte in traumatic brain injury

NPS Pharma advances pivotal REPLACE trial of NPSP-558 in hypoparathyroidism

European approval for Xiapex for Dupuytren's contracture

HIV reverse transcriptase inhibitors patented by AiCuris

Novel inhibitors of 11-beta-HSD1 presented

Selexagen discloses new sonic hedgehog protein inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...